Search

You searched for "investigation"

453 results found

Urology: a missed opportunity for medical students

1 September 2014 |
For those of us lucky enough to have medical students attached to our teams at some time during their undergraduate training, the opportunity undoubtedly represents a refreshing chance to teach well-educated and enthusiastic clinicians at the very start of their...

BXTAccelyon becomes global distribution partner for new online prostate MRI self-learning tool to enhance prostate cancer diagnosis

6 May 2020 | Contracts & Distributors
BXTAccelyon, the leading low dose rate (LDR) brachytherapy partner to hospitals and clinics worldwide, and distribution partner for PrecisionPoint™, the...

Use of MRI in the evaluation of prostate cancer: part 2

1 March 2015 | | Uroradiology, Urologic Oncology
Diffusion weighted imaging and contrast enhanced imaging Introduction Magnetic resonance imaging (MRI) is widely used in localisation, staging and post-treatment follow-up of prostate cancer. In the previous issue, we discussed the usefulness of MRI in depicting prostate anatomy and pairing...

Innovations in urology – OOPE for trainees

3 November 2022 | | Technological Developments
“Innovation is the ability to see change as an opportunity – not a threat” – Steve Jobs [1] The world is changing rapidly. Healthcare has seen a fast reform, especially as a consequence of COVID-19. Urology is a rapidly evolving...

Movember launches world’s largest cancer real world evidence network

6 December 2021
Movember has launched the world’s largest prostate cancer and testicular clinical and research network, aimed at improving the overall survival and quality of life for those living with diseases that affect over 1.4 million men worldwide every year. The leading...

FRCS – the long way round

13 March 2023 | | Technological Developments
In this series of articles I am going to show you some of the exhibits contained in the Museum of Urology, hosted on the BAUS website (www.baus.org.uk). This month I am joined by my friend and fellow member of the...

The stonecutters of 17th Century London

1 July 2015 | | Endourology and Stones, Technological Developments
In this series of articles I am going to show you some of the exhibits contained in the Museum of Urology, hosted on the BAUS website (www.baus.org.uk). In the last article I told you about the prostatic punch. If you...

In conversation with Jane Brocksom

9 March 2020
We were delighted to chat to Jane Brocksom, President of BAUN, about her background in urology nursing and plans for the association in its 25th year. Can you tell us a bit about your background and what led you into...

Prostate abscess

15 October 2021 | | Infection
Prostate abscess (PA) is a relatively uncommon clinical condition which is often difficult to diagnose because clinical symptoms are non-specific. It may be associated with a significant fatality rate, estimated to be between 3% and 30%, which may reflect its...

Meeting in the middle: a review of the rendezvous technique to treat impassable ureteric strictures and transected ureters

1 August 2015 | | Endourology and Stones, Reconstructive Urology
Introduction Complex ureteric strictures present a significant challenge with some patients undergoing multiple separate urological and radiological procedures to try to cross a stricture without success. Cross-departmental collaboration with uroradiology may allow a decrease in the number of separate interventions....

Optimising weight loss advice in obese women with urinary incontinence: a review

1 November 2018 | | Infection, Functional Urology
Background The National Institute for Health & Care Excellence (NICE) guidance specifies that women with a body mass index (BMI) of over 30, combined with urinary incontinence or overactive bladder, should be advised to lose weight [1]. A BMI over...

Trials offering cytoreductive surgery for men with de novo synchronous metastatic prostate cancer

8 November 2021 | | Basic Science Research, Urologic Oncology
Life expectancy in men diagnosed with de novo synchronous metastatic hormone-sensitive prostate cancer (mHSPC) has risen to a median of 4.8 years with upfront systemic agents (such as docetaxel) in addition to standard androgen deprivation therapy (ADT) [1-3]. Within this...